Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 23, 2007

arGentis Selects Target Health as CRO

  • arGentis Pharmaceuticals (www.argentisrx.com) chose Target Health (www.targethealth.com) as its CRO partner for upcoming clinical trials. Utilizing the company’s expertise across multiple therapeutic categories will allow arGentis to expand development capacity without requiring an increase in staff or facilities, explains Tom Davis arGentis CEO. arGentis licensed two transdermal therapies for the treatment of dry eye syndrome (DES) from the Southern College of Optometry in 2006. The company plans to submit an IND application to FDA on both products in the fourth quarter of 2007. Target Health will assist in this filing and provide all regulatory and quality deliverables throughout the clinical trial process.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »